Statens Serum Institut (SSI) is a public health institute, within the Ministry of Health in Denmark. SSI aims to ensure advanced control of infectious diseases, including new infectious and biological threats. The Institute also strives to be a highly regarded and recognized international research, and service enterprise.
Role in the TRANSVAC project
The Statens Serum Institut (SSI) Center of Vaccine Research is internationally recognised for its vaccine research and clinical pipeline. This has yielded three Tuberculosis vaccine candidates undergoing phase IIa testing and three first-in-human trials of novel CMI-inducing adjuvants. The Center has developed and produced 15 different formulations for early clinical trials (e.g. vaccine antigens produced by heterologous expression) and has conducted more than 20 clinical trials as sponsor.
Main staff involved in TRANSVAC
Peter Andersen, Vice-president and head of Vaccine R&D, PhD; Dennis Christensen: Senior Scientist, Cand Pharm PhD; Ida Svahn Rasmussen, Formulation Chemist, M.Sc.; Charlotte Green Jensen, Laboratory Manager, PhD.
The Center has a GMP pilot plant being able to produce recombinant antigens for vaccine formulations, formulation studies with the SSI CAF cased adjuvants is performed in laboratories using qualified equipment and procedures. The Center has access to state-of-the-art animal facilities including BSL3 containment, and has internationally renowned research programs on antigen discovery, the design and mechanism of CMI-inducing liposomal adjuvants, and the analysis of vaccine-induced immune responses.
TNA or Training provided
TNA1 Producing recombinant antigens using the E.Coli or L.Lactis production platform; TNA2: Formulation of vaccines using the SSI adjuvants CAF01 and CAF09b; TNA4: Production of recombinant antigens and final formulated vaccines for toxicological studies; TNA5: GMP production of recombinant antigen for vaccines; TNA8: Animal studies / TB mouse model.